Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
Spektrum der Augenheilkunde
Erschienen in:

01.10.2012 | review

Pharmakologische Basis der Anti-VEGF Therapie

verfasst von: Ao.Univ.-Prof. Dipl.-Ing. Dr. Leopold Schmetterer, Assoc. Prof. Priv.-Doz. Dr. Gerhard Garhöfer

Erschienen in: Spektrum der Augenheilkunde | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die vorliegende Übersichtsarbeit versucht unser derzeitiges Wissen bezüglicher der pharmakologischen Basis der derzeit verfügbaren anti-VEGF Therapien zusammenzufassen. Zusätzlich sollen die wichtigsten klinischen Studien und die möglichen Unterschiede zwischen den verschiedenen Behandlungskonzepten besprochen werden.
Vorheriger Artikel Editorial
Nächster Artikel Limited vitrectomy with intravitreal bevacizumab, rt-PA and gas for submacular hemorrhage due to age-related macular degeneration
Literatur
1.
Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983;219:983–5.PubMedCrossRef
2.
Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182–6.
3.
Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989;246:1306–9.PubMedCrossRef
4.
Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669–76.PubMedCrossRef
5.
Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res. 2003;22:1–29.PubMedCrossRef
6.
Vinores SA, Xiao WH, Aslam S, et al. Implication of the hypoxia response element of the Vegf promoter in mouse models of retinal and choroidal neovascularization, but not retinal vascular development. J Cell Physiol. 2006;206:749–58.PubMedCrossRef
7.
Boltz A, Luksch A, Wimpissinger B, et al. Choroidal blood flow and progression of age-related macular degeneration in the fellow eye in patients with unilateral choroidal neovascularization. Invest Ophthalmol Vis Sci. 2010;51:4220–5.PubMedCrossRef
8.
Cavalcante LL, Cavalcante ML, Murray TG, et al. Intravitreal injection analysis at the Bascom Palmer Eye Institute: evaluation of clinical indications for the treatment and incidence rates of endophthalmitis. Clin Ophthalmol. 2010;4:519–24.PubMedCrossRef
9.
Gragoudas ES, Adamis AP, Cunningham ET, Jr., Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351:2805–16.PubMedCrossRef
10.
Apte RS, Modi M, Masonson H, Patel M, Whitfield L, Adamis AP. Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration. Ophthalmology. 2007;114:1702–12.PubMedCrossRef
11.
Frenkel RE, Mani L, Toler AR, Frenkel MP. Intraocular pressure effects of pegaptanib (Macugen) injections in patients with and without glaucoma. Am J Ophthalmol. 2007;143:1034–5.PubMedCrossRef
12.
Kahook MY, Liu L, Ruzycki P, et al. High-molecular-weight aggregates in repackaged bevacizumab. Retina. 2011;30:887–92.CrossRef
13.
Liu L, Ammar DA, Ross LA, Mandava N, Kahook MY, Carpenter JF. Silicone oil microdroplets and protein aggregates in repackaged bevacizumab and ranibizumab: effects of long-term storage and product mishandling. Invest Ophthalmol Vis Sci. 2011;52:1023–34.PubMedCrossRef
14.
Meyer CH, Holz FG. Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab. Eye (Lond). 2011;25:661–72.CrossRef
15.
Peters S, Julien S, Heiduschka P, et al. Antipermeability and antiproliferative effects of standard and frozen bevacizumab on choroidal endothelial cells. Br J Ophthalmol. 2007;91:827–31.PubMedCrossRef
16.
Ferrara N, Damico L, Shams N, Lowman H, Kim R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006;26:859–70.PubMedCrossRef
17.
Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3:391–400.PubMedCrossRef
18.
Chen Y, Wiesmann C, Fuh G, et al. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J Mol Biol. 1999;293:865–81.PubMedCrossRef
19.
Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–31.PubMedCrossRef
20.
Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432–44.PubMedCrossRef
21.
Nguyen TT, Wong TY. Retinal vascular changes and diabetic retinopathy. Curr Diab Rep. 2009;9:277–83.PubMedCrossRef
22.
Heier JS, Boyer D, Nguyen QD, et al. The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing. Ophthalmology. 2011;118:1098–106.PubMedCrossRef
23.
Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007;143:566–83.PubMedCrossRef
24.
Gerding H, Loukopoulos V, Riese J, Hefner L, Timmermann M. Results of flexible ranibizumab treatment in age-related macular degeneration and search for parameters with impact on outcome. Graefes Arch Clin Exp Ophthalmol. 2011;249:653–62.PubMedCrossRef
25.
Holz FG, Korobelnik JF, Lanzetta P, et al. The effects of a flexible visual acuity-driven ranibizumab treatment regimen in age-related macular degeneration: outcomes of a drug and disease model. Invest Ophthalmol Vis Sci. 2010;51:405–12.PubMedCrossRef
26.
Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364:1897–908.PubMedCrossRef
27.
Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2005;36:331–5.PubMed
28.
Costa R, Carneiro A, Rocha A, et al. Bevacizumab and ranibizumab on microvascular endothelial cells: a comparative study. J Cell Biochem. 2009;108:1410–7.PubMedCrossRef
29.
Carneiro A, Falcao M, Pirraco A, Milheiro-Oliveira P, Falcao-Reis F, Soares R. Comparative effects of bevacizumab, ranibizumab and pegaptanib at intravitreal dose range on endothelial cells. Exp Eye Res. 2009;88:522–7.PubMedCrossRef
30.
Klettner AK, Kruse ML, Meyer T, Wesch D, Kabelitz D, Roider J. Different properties of VEGF-antagonists: Bevacizumab but not Ranibizumab accumulates in RPE cells. Graefes Arch Clin Exp Ophthalmol 2009;247:1601–8.
31.
Heiduschka P, Fietz H, Hofmeister S, et al. Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci. 2007;48:2814–23.PubMedCrossRef
32.
Ding X, Patel M, Chan CC. Molecular pathology of age-related macular degeneration. Prog Retin Eye Res. 2009;28:1–18.PubMedCrossRef
33.
King GL. The role of inflammatory cytokines in diabetes and its complications. J Periodontol. 2008;79:1527–34.PubMedCrossRef
34.
Scappaticci FA, Fehrenbacher L, Cartwright T, et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol. 2005;91:173–80.PubMedCrossRef
35.
Zhu X, Wu S, Dahut WL, Parikh CR. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis. 2007;49:186–93.PubMedCrossRef
36.
Mendrinos E, Mangioris G, Papadopoulou D, Donati G, Pournaras C. One year results of the effect of intravitreal ranibizumab on the retinal arteriolar diameter in patients with neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2011 Dec 13. In press, [Epub ahead of print].
37.
Sacu S, Pemp B, Weigert G, et al. Response of retinal vessels and retrobulbar hemodynamics to intravitreal anti-VEGF treatment in eyes with branch retinal vein occlusion. Invest Ophthalmol Vis Sci. 2010;52:3046–50.CrossRef
38.
Bakri SJ, Risco M, Edwards AO, Pulido JS. Bilateral simultaneous intravitreal injections in the office setting. Am J Ophthalmol. 2009;148:66–9.e1.PubMedCrossRef
39.
Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology. 2007;114:2179–82.PubMedCrossRef
40.
Bhisitkul RB. Vascular endothelial growth factor biology: clinical implications for ocular treatments. Br J Ophthalmol. 2006;90:1542–7.PubMedCrossRef
41.
Matsuyama K, Ogata N, Matsuoka M, Wada M, Takahashi K, Nishimura T. Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab. Br J Ophthalmol. 2010;94:1215–8.PubMedCrossRef
42.
Wong TY, Liew G, Mitchell P. Clinical update: new treatments for age-related macular degeneration. Lancet. 2007;370:204–6.PubMedCrossRef
43.
Lockhart AC, Rothenberg ML, Dupont J, et al. Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol. 2010;28:207–14.PubMedCrossRef
44.
Gillies MC, Wong TY. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2007;356:748–9 (author reply 749–50).PubMed
45.
Wu L, Arevalo JF, Roca JA, et al. Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up. Retina. 2008;28:212–9.PubMedCrossRef
46.
Mason JO, 3rd, Frederick PA, Neimkin MG, et al. Incidence of hemorrhagic complications after intravitreal bevacizumab (avastin) or ranibizumab (lucentis) injections on systemically anticoagulated patients. Retina. 2010;30:1386–9.PubMedCrossRef
47.
Curtis LH, Hammill BG, Schulman KA, Cousins SW. Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol. 2010;128:1273–9.PubMedCrossRef
48.
Schmucker C, Antes G, Lelgemann M. A systematic review on the effect of bevacizumab in exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2010;248:451–2 (author reply 453–4).PubMedCrossRef
49.
Subramanian ML, Abedi G, Ness S, et al. Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial. Eye (Lond). 2010;24:1708–15.CrossRef
50.
Ip MS, Scott IU, Brown GC, et al. Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology. Ophthalmology. 2008;115:1837–46.PubMedCrossRef
51.
Massin P, Bandello F, Garweg JG, Hansen LL, Harding SP, Larsen M, Mitchell P, Sharp D, Wolf-Schnurrbusch UE, Gekkieva M, Weichselberger A, Wolf S. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care. 2010;33:2399–405.PubMedCrossRef
Metadaten
Titel
Pharmakologische Basis der Anti-VEGF Therapie
verfasst von
Ao.Univ.-Prof. Dipl.-Ing. Dr. Leopold Schmetterer
Assoc. Prof. Priv.-Doz. Dr. Gerhard Garhöfer
Publikationsdatum
01.10.2012
Verlag
Springer Vienna
Erschienen in
Spektrum der Augenheilkunde / Ausgabe 4/2012
Print ISSN: 0930-4282
Elektronische ISSN: 1613-7523
DOI
https://doi.org/10.1007/s00717-012-0110-0

Weitere Artikel der Ausgabe 4/2012

Limited vitrectomy with intravitreal bevacizumab, rt-PA and gas for submacular hemorrhage due to age-related macular degeneration

  • original article

Editorial

  • editorial

Entwicklung und Implementierung eines Leitbildes an der Universitäts-Augenklinik Graz

  • originalarbeit

Risikofaktoren retinaler Arterienverschlüsse

  • originalarbeit

Univ. Prof. Dr. Karlheinz Schenk 1925–2012

  • berichte und interviews

Hat sich das Altersprofil der Kataraktpatienten in den letzten 14 Jahren geändert? Eine Analyse von 76.760 Phakoemulsifikationen

  • originalarbeit